Kuno T, et al. - Researchers analyzed the studies from MEDLINE and EMBASE that reported the influences of different renin-angiotensin-aldosterone system (RAAS) antagonists among patients with heart failure with preserved ejection fraction (HFpEF). The included studies were randomized controlled studies. All-cause death, trial defined cardiovascular mortality and heart failure (HF) hospitalizations were the chief outcomes. Experts analyzed data from 5 eligible clinical trials (PEP-CHF, perindopril; CHARM-preserved, candesartan; I-PRESERVE, irbesartan; TOPCAT, spironolactone; PARAGON-HF, sacubitril-valsartan and valsartan) with 10,523 on RAAS antagonists and 6,259 controls. Findings revealed no influence of RAAS antagonists on mortality but revealed lower HF hospitalizations in relation to the combination of sacubitril-valsartan among patients with HFpEF.